Does HRCT Pattern Influence the Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases?

被引：0

作者：

Brown, K. K. ^{[1
]}

Walsh, S. L. F. ^{[2
]}

Devaraj, A. ^{[3
]}

Song, J. ^{[4
]}

Wuyts, W. A. ^{[5
]}

Valenzuela, C. ^{[6
]}

Goeldner, R. ^{[7
]}

Stowasser, S. ^{[8
]}

Schlenker-Herceg, R. ^{[9
]}

Wells, A. U. ^{[2
,10
]}

机构：

[1] Natl Jewish Hlth, Pulm Crit Care & Sleep Med, Denver, CO USA

[2] Imperial Coll, Natl Heart & Lung Inst, London, England

[3] Royal Brompton & Harefield NHS Fdn Trust, Dept Radiol, London, England

[4] Univ Ulsan, Asan Med Ctr, Pulm & Crit Care Med, Coll Med, Seoul, South Korea

[5] Univ Hosp Leuven, Dept Resp Med, Unit Interstitial Lung Dis, Leuven, Belgium

[6] Hosp Univ La Princesa, Madrid, Spain

[7] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

[8] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[9] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA

[10] Royal Brompton & Harefield NHS Fdn, Natl Inst Hlth Res Resp Biomed Res Unit, London, England

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A1507

引用

页数：2

共 50 条

[41] Effects of nintedanib on dyspnoe, cough and quality of life in patients with progressive fibrosing interstitial lung diseases: findings from the INBUILD trial
Kreuter, M.
Swigris, J. J.
Richeldi, L.
Wijsenbeek, M.
Nunes, H.
Suda, T.
James, A.
Rohr, K. B.
Quaresma, M.
Flaherty, K. R.
PNEUMOLOGIE, 2021, 75 : S24 - S24
[42] Effects of Nintedanib on Dyspnea, Cough and Quality of Life in Patients with Progressive Fibrosing Interstitial Lung Diseases: Findings from the INBUILD Trial
Swigris, J. J.
Richeldi, L.
Wijsenbeek, M.
Kreuter, M.
Nunes, H.
Suda, T.
James, A.
Rohr, K. B.
Quaresma, M.
Flaherty, K. R.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[43] The natural history of progressive fibrosing interstitial lung diseases
Kolb, Martin
Vasakova, Martina
RESPIRATORY RESEARCH, 2019, 20 (1)
[44] Importance of chest HRCT in the diagnostic evaluation of fibrosing interstitial lung diseases
Teixeira e Silva Torres, Pedro Paulo
Rabahi, Marcelo Fouad
do Carmo Moreira, Maria Auxiliadora
Escuissato, Dante Luiz
Portes Meirelles, Gustavo de Souza
Marchiori, Edson
JORNAL BRASILEIRO DE PNEUMOLOGIA, 2021, 47 (03)
[45] Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective
Albera, Carlo
Verri, Giulia
Sciarrone, Federico
Sitia, Elena
Mangiapia, Mauro
Solidoro, Paolo
BIOMEDICINES, 2021, 9 (09)
[46] The natural history of progressive fibrosing interstitial lung diseases
Martin Kolb
Martina Vašáková
Respiratory Research, 20
[47] The natural history of progressive fibrosing interstitial lung diseases
Brown, Kevin K.
Martinez, Fernando J.
Walsh, Simon L. F.
Thannickal, Victor J.
Prasse, Antje
Schlenker-Herceg, Rozsa
Goeldner, Rainer-Georg
Clerisme-Beaty, Emmanuelle
Tetzlaff, Kay
Cottin, Vincent
Wells, Athol U.
EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (06)
[48] Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases
Chen, Xianqiu
Guo, Jian
Yu, Dong
Jie, Bing
Zhou, Ying
FRONTIERS IN PHARMACOLOGY, 2021, 12
[49] The Burden of Progressive-Fibrosing Interstitial Lung Diseases
Cottin, Vincent
Teague, Rhiannon
Nicholson, Lindsay
Langham, Sue
Baldwin, Mike
FRONTIERS IN MEDICINE, 2022, 9
[50] NATIONAL UK EXPERIENCE OF THE TREATMENT OF PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE WITH NINTEDANIB
Dixon, G.
Hague, S.
Thould, H.
Khin, A. M. N.
Mulholland, S.
Gibbons, M.
Barratt, S. L.
THORAX, 2023, 78 (SUPPL_4) : A11 - A12

← 1 2 3 4 5 →